Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.39 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.39 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.39 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.39 |
| ▸ | NPEPPS | P55786 | 10/20 | 0.39 |
| ▸ | ANPEP | P15144 | 7/20 | 0.39 |
| ▸ | TYMP | P19971 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26808463 | 0.83 | LMNA (0.55) | LMNAADORA2AADORA2BP2RX3P2RX4 | |
| SCHEMBL26808236 | 0.80 | LMNA (0.52) | LMNAADORA2AADORA2BP2RX3P2RX4 | |
| SCHEMBL26808216 | 0.80 | LMNA (0.52) | LMNAADORA2AADORA2BP2RX3P2RX4 | |
| SCHEMBL26808544 | 0.80 | LMNA (0.51) | LMNAADORA2AADORA2BP2RX3P2RX4 | |
| SCHEMBL23046811 | 0.79 | ADORA1 (0.48) | ADORA2AADORA2BADORA1 | |
| SCHEMBL29313524 | 0.79 | LMNA (0.58) | LMNAADORA2AADORA2BNPEPPSANPEP | |
| SCHEMBL20482906 | 0.78 | LMNA (0.64) | LMNAADORA2AADORA2BNPEPPSANPEP | |
| SCHEMBL22206844 | 0.77 | PRMT6 (0.50) | P2RX3P2RX4P2RX2ADORA1 | |
| SCHEMBL23629911 | 0.77 | LMNA (0.45) | LMNAP2RX3P2RX4P2RX2ADORA1 | |
| SCHEMBL23566752 | 0.76 | LMNA (0.47) | LMNAADORA2AP2RX3P2RX4P2RX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250041324-A1 | CYCLIC DINUCLEOTIDES AS AGONISTS OF STIMULATOR OF INTERFERON GENE DEPENDENT SIGNALLING | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2025-02-06 | — | — | US | disclosed |
| US-12036231-B2 | Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-07-16 | — | — | US | disclosed |
| US-20220347201-A1 | CYCLIC DINUCLEOTIDES AS AGONISTS OF STIMULATOR OF INTERFERON GENE DEPENDENT SIGNALLING | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2022-11-03 | — | — | US | disclosed |
| US-11400108-B2 | Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-08-02 | — | — | US | disclosed |
| US-20210236531-A1 | CYCLIC DINUCLEOTIDES AS AGONISTS OF STIMULATOR OF INTERFERON GENE DEPENDENT SIGNALLING | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2021-08-05 | — | — | US | disclosed |
| US-10933078-B2 | Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-03-02 | — | — | US | disclosed |
| WO-2018156625-A1 | CYCLIC DINUCLEOTIDES AS AGONISTS OF STIMULATOR OF INTERFERON GENE DEPENDENT SIGNALLING | BOARD OF REGENTS,THE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11400108-B2 | Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling | STING1, IRF3, CGAS | LMNA 4166/4885ADORA2A 304/4885ADORA2B 636/4885 |
| US-12036231-B2 | Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling | STING1, IRF3, CGAS | LMNA 4166/4885ADORA2A 304/4885ADORA2B 636/4885 |
| US-20250041324-A1 | CYCLIC DINUCLEOTIDES AS AGONISTS OF STIMULATOR OF INTERFERON GENE DEPENDENT SIGNALLING | STING1, IRF3, CGAS | LMNA 4166/4885ADORA2A 304/4885ADORA2B 636/4885 |
| US-20220347201-A1 | CYCLIC DINUCLEOTIDES AS AGONISTS OF STIMULATOR OF INTERFERON GENE DEPENDENT SIGNALLING | STING1, IRF3, CGAS | LMNA 4166/4885ADORA2A 304/4885ADORA2B 636/4885 |
| US-20210236531-A1 | CYCLIC DINUCLEOTIDES AS AGONISTS OF STIMULATOR OF INTERFERON GENE DEPENDENT SIGNALLING | STING1, IRF3, CGAS | LMNA 4166/4885ADORA2A 304/4885ADORA2B 636/4885 |
| US-10933078-B2 | Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling | STING1, IRF3, CGAS | LMNA 4166/4885ADORA2A 304/4885ADORA2B 636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.